School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Department of Respirology & Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
Int Immunopharmacol. 2024 Mar 30;130:111778. doi: 10.1016/j.intimp.2024.111778. Epub 2024 Mar 2.
To investigate the mechanism of action of fatty acid receptors, FFAR1 and FFAR4, on ulcerative colitis (UC) through fatty acid metabolism and macrophage polarization.
Dextran sulfate sodium (DSS)-induced mouse model of UC mice was used to evaluate the efficacy of FFAR1 (GW9508) and FFAR4 (GSK137647) agonists by analyzing body weight, colon length, disease activity index (DAI), and histological scores. Real-time PCR and immunofluorescence analysis were performed to quantify the levels of fatty acid metabolizing enzymes and macrophage makers. FFA-induced lipid accumulation in RAW264.7 cells was visualized by Oil Red O staining analysis, and cells were collected to detect macrophage polarization by flow cytometry.
The combination of GW9508 and GSK137647 significantly improved DSS-induced UC symptoms, caused recovery in colon length, and decreased histological injury. GW9508 + GSK137647 treatment upregulated the expressions of CD206, lipid oxidation enzyme (CPT-1α) and anti-inflammatory cytokines (IL-4, IL-10, IL-13) but downregulated those of CD86, lipogenic enzymes (ACC1, FASN, SCD1), and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Combining the two agonists decreased FFA-induced lipid accumulation and increased CD206 expression in cell-based experiments.
Activated FFAR1 and FFAR4 ameliorates DSS-induced UC by promoting fatty acid metabolism to reduce lipid accumulation and mediate M2 macrophage polarization.
通过脂肪酸代谢和巨噬细胞极化研究脂肪酸受体 FFAR1 和 FFAR4 在溃疡性结肠炎(UC)中的作用机制。
采用葡聚糖硫酸钠(DSS)诱导的 UC 小鼠模型,通过分析体重、结肠长度、疾病活动指数(DAI)和组织学评分,评估 FFAR1(GW9508)和 FFAR4(GSK137647)激动剂的疗效。实时 PCR 和免疫荧光分析用于定量脂肪酸代谢酶和巨噬细胞标志物的水平。油红 O 染色分析显示 FFA 诱导 RAW264.7 细胞中的脂质积累,并用流式细胞术检测巨噬细胞极化。
GW9508 和 GSK137647 的联合治疗显著改善了 DSS 诱导的 UC 症状,导致结肠长度恢复,组织学损伤减轻。GW9508+GSK137647 治疗上调了 CD206、脂质氧化酶(CPT-1α)和抗炎细胞因子(IL-4、IL-10、IL-13)的表达,但下调了 CD86、脂肪生成酶(ACC1、FASN、SCD1)和促炎细胞因子(IL-1β、IL-6、TNF-α)的表达。在细胞实验中,两种激动剂联合使用可减少 FFA 诱导的脂质积累并增加 CD206 的表达。
激活 FFAR1 和 FFAR4 通过促进脂肪酸代谢减少脂质积累并介导 M2 巨噬细胞极化来改善 DSS 诱导的 UC。